ERBB2 and sarcoma: To date, the most positive trials reported have used GD2 CARs to target neuroblastoma (3 of 11 patients with complete remissions), HER2 CARs for sarcoma (4 of 17 patients showing stable disease), and HER1 CARs for lung cancer (2 of 11 patients with partial responses) (30).